Health Ministry Advisory on Stem Cell Therapy

Background

  • The Union Ministry of Health and Family Welfare issued a comprehensive advisory to all States and UTs to strictly regulate stem cell therapy.
  • Issued in compliance with the Supreme Court's January 2026 judgment in Yash Charitable Trust & Ors. v. Union of India, which stressed penalizing unauthorized and unscientific use of stem cell therapies.

Key Highlights of the Advisory

  • Standard Care vs. Experimental Therapy: Stem cell therapy as standard clinical care is permitted only for Ministry-approved indications (e.g., specific blood cancers and haematologic disorders).
  • Autism Spectrum Disorder (ASD): Therapeutic use of any stem cell for ASD is restricted to approved clinical trials; unproven interventions cannot be marketed as standard commercial treatments.
  • Compliance: Clinical trials must follow the National Guidelines for Stem Cell Research (NGSCR), 2017, jointly issued by ICMR and DBT.
  • Penalties:
  • Unauthorized administration/promotion/advertisement = professional misconduct under Indian Medical Council (IMC) Regulations, 2002; disciplinary action by State Medical Councils (NMC reiterated this).
  • Establishments face penalties and cancellation of registration under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act, 2010.

What is Stem Cell Therapy?

  • Also called regenerative medicine; uses stem cells to repair, regenerate or replace damaged/diseased tissues.
  • Stem cells are undifferentiated "master cells" with two core properties:
  • Self-Renewal: continuous division into identical copies.
  • Differentiation: maturing into specialized cell types.
  • Types of Stem Cells:
  • Embryonic Stem Cells: pluripotent, derived from embryos.
  • Adult Stem Cells: multipotent, found in bone marrow, fat, etc.
  • Induced Pluripotent Stem Cells (iPSCs): adult cells genetically reprogrammed to behave like embryonic stem cells.
  • Perinatal Stem Cells: from placenta, umbilical cord blood, amniotic fluid.
  • Mechanism: Harvested from patient (autologous) or donor (allogeneic), processed, and administered via infusion/injection/implantation; cells home to injured tissue, differentiate, and release growth factors/cytokines.
  • Clinical Status:
  • Established: Haematopoietic stem-cell transplantation (bone marrow transplant) for blood cancers (Leukemia) and disorders (Thalassemia).
  • Experimental: Neurological conditions — Autism, Alzheimer's, Parkinson's.
  • Risks: Tumour formation, unintended differentiation, immune complications, infections, embolisms, neurological damage; ethical concerns with embryonic stem cell research.

Regulatory Framework in India

  • NGSCR, 2017: Ethical/scientific framework; categorizes research as permitted, restricted, prohibited.
  • Drugs and Cosmetics Act, 1940 & New Drugs and Clinical Trials Rules, 2019: Stem cell-derived products (SCDPs) classified as "New Drugs"; require CDSCO approval before commercialization.
  • Clinical Establishments Act, 2010: Regulates hospitals/clinics; basis for registration cancellation of rogue clinics.